Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Patterson

Showing results (191-200 of 277) with videos related to

Pageof 28
Sort By:
Cancer Biology & Therapy|April 15, 2015
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinomaMaria R Abbattista, Stephen M F Jamieson, Yongchuan Gu, et al.
Psychological Medicine|May 18, 2021
Effectiveness and comparative effectiveness of evidence-based psychotherapies for posttraumatic stress disorder in clinical practiceShira Maguen, Erin Madden, Nicholas Holder, et al.
Journal of Affective Disorders|June 21, 2020
Cognitive Processing Therapy for Veterans with Posttraumatic Stress Disorder: What is the Median Effective Dose?Nicholas Holder, Brian Shiner, Yongmei Li, et al.
Molecular Pharmacology|October 11, 2011
Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxiaChristopher P Guise, Maria R Abbattista, Smitha R Tipparaju, et al.
Cognitive Behaviour Therapy|April 27, 2022
Veterans receiving a second course of cognitive processing therapy or prolonged exposure therapy: is it better to switch or stay the same?Nicholas Holder, Adam J Batten, Brian Shiner, et al.
International Journal of Molecular Sciences|June 27, 2024
Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623Abigail V Sharrock, Jeff S Mumm, Elsie M Williams, et al.
Biological Psychiatry|June 17, 1998
Is P50 suppression a measure of sensory gating in schizophrenia?Y Jin, W E Bunney, C A Sandman, et al.
Cancers|July 2, 2016
Advancing Clostridia to Clinical Trial: Past Lessons and Recent ProgressAlexandra M Mowday, Christopher P Guise, David F Ackerley, et al.
International Journal of Radiation Oncology, Biology, Physics|April 27, 2005
Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cellsNaomi Chadderton, Rachel L Cowen, Freda C D Sheppard, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|March 21, 2022
Launching into clinical space with medspaCy: a new clinical text processing toolkit in PythonHannah Eyre, Alec B Chapman, Kelly S Peterson, et al.
Pageof 28

Showing results (191-200 of 277) with videos related to

Sort By:
Pageof 28
Cancer Biology & Therapy|April 15, 2015
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinomaMaria R Abbattista, Stephen M F Jamieson, Yongchuan Gu, et al.
Psychological Medicine|May 18, 2021
Effectiveness and comparative effectiveness of evidence-based psychotherapies for posttraumatic stress disorder in clinical practiceShira Maguen, Erin Madden, Nicholas Holder, et al.
Journal of Affective Disorders|June 21, 2020
Cognitive Processing Therapy for Veterans with Posttraumatic Stress Disorder: What is the Median Effective Dose?Nicholas Holder, Brian Shiner, Yongmei Li, et al.
Molecular Pharmacology|October 11, 2011
Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxiaChristopher P Guise, Maria R Abbattista, Smitha R Tipparaju, et al.
Cognitive Behaviour Therapy|April 27, 2022
Veterans receiving a second course of cognitive processing therapy or prolonged exposure therapy: is it better to switch or stay the same?Nicholas Holder, Adam J Batten, Brian Shiner, et al.
International Journal of Molecular Sciences|June 27, 2024
Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623Abigail V Sharrock, Jeff S Mumm, Elsie M Williams, et al.
Biological Psychiatry|June 17, 1998
Is P50 suppression a measure of sensory gating in schizophrenia?Y Jin, W E Bunney, C A Sandman, et al.
Cancers|July 2, 2016
Advancing Clostridia to Clinical Trial: Past Lessons and Recent ProgressAlexandra M Mowday, Christopher P Guise, David F Ackerley, et al.
International Journal of Radiation Oncology, Biology, Physics|April 27, 2005
Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cellsNaomi Chadderton, Rachel L Cowen, Freda C D Sheppard, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|March 21, 2022
Launching into clinical space with medspaCy: a new clinical text processing toolkit in PythonHannah Eyre, Alec B Chapman, Kelly S Peterson, et al.
Pageof 28